Background: Lenticulostriate vasculopathy is associated with various disorders, in particular cytomegalovirus infection, which can cause neurological consequences. We wanted to evaluate the association of lenticulostriate vasculopathy and cytomegalovirus infection. We retrospectively collected data on lenticulostriate vasculopathy from 858 neonatal ultrasonography scans. Methods: Fifty-five patients with lenticulostriate vasculopathy were diagnosed. Lenticulostriate vasculopathy was classified as severe and mild according to the ultrasonographic findings. We analyzed gender, unilateral and bilateral lenticulostriate vasculopathy, mild and severe lenticulostriate vasculopathy, intrauterine growth retardation, and lenticulostriate vasculopathy associated with other brain malformations to determine whether they were correlated with cytomegalovirus infection. Results: Neonatal cytomegalovirus infections correlated primarily with lenticulostriate vasculopathy that was associated with brain structure anomalies p < 0.0001, followed by severe lenticulostriate vasculopathy (p Z 0.029). Cytomegalovirus urine polymerase chain reaction ratios were 69% for severe and 23% for mild lenticulostriate vasculopathy (p Z 0.002; odds ratio Z 7.33). Of 72 newborns with intrauterine growth retardation without lenticulostriate vasculopathy, 33 were analyzed for cytomegalovirus, of whom only one was positive, which was significantly different from the newborns with lenticulostriate vasculopathy (p Z 0.003; odds ratio Z 11.64). Conclusion: Lenticulostriate vasculopathy on neonatal ultrasonography is useful for predicting cytomegalovirus infection, particularly in severe lenticulostriate vasculopathy. When severe lenticulostriate vasculopathy is associated with a brain structure anomaly, cytomegalovirus infection should be considered. The outcomes for the cases in which cytomegalovirus infection was associated with other brain structure anomalies were significantly worse than the outcomes in cases associated with lenticulostriate vasculopathy only.
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Introduction
Congenital cytomegalovirus (CMV) infection is not uncommon and has been reported to occur in 0.5e2% of all live births.
1e4 It can cause severe neurological consequences such as hearing loss, neurodevelopmental disability, and epilepsy. About 40,000 newborns a year (accounting for 1% of all births in the USA) have been reported to have congenital CMV, 1 and about 5e10% of children with an asymptomatic CMV infection and 40e50% of those with a symptomatic CMV infection will develop hearing loss. 5 Symptomatic disease is characterized by signs including microcephaly, hearing loss, migrational brain disorder, jaundice, petechiae, hepatosplenomegaly, purpura, seizures, lethargy, hypotonia, and poor suck. 1, 6, 7 Additional examinations such as polymerase chain reaction (PCR) of CMV in urine DNA are suggested for patients with clinical presentations, and brain magnetic resonance imaging (MRI) findings such as ventriculomegaly, polymicrogyria, calcification, cerebellar hypoplasia, and periventricular white matter damage. However, as these unspecific findings are not sufficient enough to diagnose asymptomatic CMV without performing tests for CMV infection, prompt medication therapy may be delayed resulting in hearing loss.
8e11 Antiviral treatment for newborns with congenital CMV infection without evidence of newborn disease is controversial, especially for the prevention of hearing impairment. 10 The definition of lenticulostriate vasculopathy (LSV) is based on lesions visible on an ultrasound of the brain, appearing as echogenic streaks or spots in the arteries of the thalamus and basal ganglia. 12 LSV has been reported to be associated with various congenital disorders including chromosomal anomalies and congenital infections such as CMV, and it has been reported to occur in 0.4e5.8% of neonates who have undergone brain ultrasonography. 6, 13, 14 In one study, 12 transfontanelar color Doppler was shown to display lenticulostriatal blood flow and was used to assess Stage I LSV (with flow within echogenic changes) and Stage II LSV (in which the flow disappears, despite the presence of streaks and spots, which at this stage most probably corresponds to calcification). However, the reported etiologies and outcomes of newborns with LSV are inconsistent, 6,12e17 which is probably associated with late sensorineural hearing damage and postnatal CMV infections not found in initial brain ultrasonography. 6, 16 Most neonates with CMV infection who are asymptomatic are undetected, especially those with a congenital but previously unknown CMV infection, and this can eventually result in the development of impairments.
2 Therefore, it is important to carefully review and correctly interpret brain ultrasonographic findings for CMV infection in at-risk neonates.
In comparison to the reported universal CMV screening tests, brain ultrasonography is a simple and relatively inexpensive tool that can be used to evaluate LSV, which may be associated with CMV infection. As the relationship between LSV and CMV infection is not currently fully understood, the aim of this study was to evaluate this association in neonates.
Materials and methods
We retrospectively collected data on LSV from brain ultrasonography scans of 858 newborns between June 2010 and May 2012. LSV was defined as multiple or single linear echogenicity in a bilateral or unilateral basal ganglion or thalamus. Brain ultrasonography scans were routinely performed in all infants admitted to the neonatal intensive care unit (NICU, level III) and specialty care nursery (level II), and outpatients. We measured the diameter of the LSV lines using an ultrasound system (Acuson X300; Siemens Medical Solutions USA, Malvern, PA, USA).
LSV cases were categorized into two groups: severe LSV, at least one line !2.5 mm in brain ultrasonography ( Figure 1B) ; and mild LSV, echogenic lines < 2.5 mm ( Figure 1A ). Congenital CMV infection was defined as a virus detected by urine PCR up to 3 weeks after birth, and postnatal infection was defined as a virus detected by urine PCR from >3 weeks to 12 months after birth.
Gender, unilateral and bilateral LSV in the brain, mild and severe LSV (Figure 1 ), intrauterine growth retardation (IUGR), and LSV associated with brain structural malformations ( Figure 2 ) were analyzed to investigate their association with CMV infection. We also enrolled 72 newborns with isolated IUGR (50% were symmetric and 50% were asymmetric) but without LSV as the control group. Intelligence quotients were measured according to age and classified into cognition and performance quotients. The scales of cognition and performance quotients were categorized as: normal (>85), mildly retarded (70e85), moderately retarded (from 50 to < 70), and severely retarded (<50). We classified the neurodevelopmental outcomes of the patients with CMV into four groups: no neurological signs and no developmental delay milestones; mild developmental delay; moderate developmental delay; and severe developmental delay. At the last follow-up, the patients were aged between 18 months and 36 months. The study protocol was approved by the Institute's Committee on Human Research of Chung Shan Medical University Hospital (IRB NO.:CS2-15026).
Categorical variables associated with the IUGR and LSV groups were divided into antenatal, perinatal, and postnatal. The IUGR patients without LSV had only antenatal risk factors. The antenatal risk factors associated with IUGR included placental insufficiency, congenital anomalies, infections, or drug and substance misuse. The antenatal, perinatal, and postnatal risk factors associated with LSV included intrauterine infection (mainly CMV), chromosomal aberrations, infants of diabetic mothers, intrauterine growth retardation, hypoxic/ischemic conditions during the delivery process, and central nervous system infections. Categorical variables between groups were analyzed by using an independent t test. Linear regression analysis was used to determine significance and the correlation coefficients. All statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). 
Results

Data analysis
Fifty-five (6.4%) patients were diagnosed with LSV, of whom 44 (80%) were in the NICU, seven (13%) were in the specialty care nursery, and four (7%) were outpatients (Table S1 ). The etiologies associated with LSV were CMV (n Z 20), chromosome anomalies (n Z 5), those other than brain congenital anomalies (n Z 8), those other than CMV infections (n Z 7), encephalopathy (n Z 5), and unknown (n Z 10).
Of the 55 newborns with LSV, 16 were severe and 39 were mild cases (Table S2 ). The CMV urine PCR ratios were 69% in those with severe LSV and 23% in those with mild LSV [p Z 0.002; odds ratio (OR) Z 7.33; 95% confidence interval (CI) Z 1.40e38.43]. Neonatal CMV infections were most significantly correlated with brain ultrasonography showing LSV and were associated with brain structure anomalies (p < 0.001), followed by severe LSV (p Z 0.027; correlation coefficient: 0.260; Tables 1 and 2 ). The other factors were not significant. Of the 11 newborns with severe LSV and associated brain-structure anomalies, 10 had CMV infections and one had trisomy 13. In the IUGR group (72 newborns with IUGR without LSV) (Table S1 ), 33 were analyzed using CMV urine PCR and only one was found to be positive, which was significantly different from the newborns with LSV (p Z 0.003; OR Z 11.64; 95% CI Z 0.81e166.53).
Developmental and neurodevelopmental outcomes
Of the 20 newborns (10 males, 10 females) with CMV, 11 were term (gestational age 38 weeks) and nine were preterm. Seventeen infants had early developmental delays, and 10 had a low body weight after follow-up (Table 3) . Three had hearing loss, including two with nonpickup w95 dB, and one at 40 dB who improved to 30 dB after ganciclovir treatment for 1 year.
Eighteen (90%) of the 20 newborns with a CMV-infection had developmental delays, including nine with mild, four with moderate, and five with severe delays. The outcomes of the term and preterm infants were not significantly different. The neurodevelopmental outcomes of those with CMV infections in the two groups were not significantly different, however the outcomes for 15 cases in whom CMV infection was associated with other brain structural anomalies found using MRI or computed tomography were significantly worse than the outcomes in the cases associated with LSV only (p Z 0.029; Table 3 ).
Discussion
We found that the severity of LSV was strongly associated with CMV infection. Even though many factors, including exogenous and endogenous factors may result in LSV findings, however their exact pathological mechanisms are unclear. It is thought that prenatal, intrapartum, or post natal brain insults from hypoxia, ischemia, or inflammation/calcification in these vessels leads to subtle vascular changes, where the regions with relatively high blood flow such as the basal ganglia and thalamus bear the brunt. 6, 12, 16, 17 In addition, LSV was a more powerful predictor of CMV than IUGR, particularly when LSV was associated with brain structural anomalies. By contrast, no patients with IUGR had LSV, and only one had CMV. Isolated IUGR without other anomalies therefore carried a lower risk for CMV. This suggests that when brain ultrasonography 
AgCC Z agenesis of the corpus callosum; C Z congenital; DD Z developmental delay; IUGR Z intrauterine growth retardation; N/A Z not available; P Z post infection. * Neurodevelopment (Groups 1e4): Group 1, no neurological signs and no delay in developmental milestones; Group 2 (mild), mild developmental delay; Group 3 (moderate), moderate developmental delay; and Group 4 (severe), severe developmental delay; time of infection (C/P).
y Hearing deficiency was defined by the most quiet sounds their better ear could hear were above 30 dB. z Cases 3, 8, 18, and 16 were LBW infants, and Cases 5 and 19 were VLBW infants.
shows LSV, a test for CMV should be performed, particularly when the echogenicity of the LSV is marked and multilinear. The outcomes for cases in whom CMV infection was associated with other brain structural anomalies were significantly worse than the outcomes in cases associated with LSV only. Universal CMV screening tests using a dried blood sample obtained shortly after birth are currently in use; however, for regions without a policy of routine PCR screening for CMV, brain ultrasonography can be used as an alternative tool to detect CMV, particularly in asymptomatic newborns. Universal screening of hearing in newborns is currently performed in many countries. However, Fowler et al 18 reported that no CMV infections were identified during hearing screening because the majority of CMV infections involve a delayed onset of hearing loss which is asymptomatic at birth. Neonatal screening of hearing alone is therefore insufficient to detect all neonates with CMV infection because most infants with congenital CMV have normal hearing in the neonatal stage. 19 Reports of imaging findings for CMV vary.
19e21 One study 22 reported that ventricular dilatation was the most common fetal ultrasonographic and MRI finding, followed by periventricular calcification, microcephaly, and subependymal cyst. One case report 21 reported that congenital CMV was a cause of temporal cysts. However, in our case series, we found that congenital cysts could occur in any region, as in Patient 6, who had occipital porencephaly, and Patient 7, who had a temporal cyst ( Figure S1 ). Our findings underscore the importance of brain ultrasonographic findings of congenital and acquired CMV, including basal ganglion or thalamus hyperechogenicity, ventriculomegaly, and destructive brain lesions (including brain cysts in any region of the brain that should be highly suggestive of a CMV infection). Our imaging findings showed that MRI increased the positive predictive value but that ultrasonography and MRI were not mutually exclusive, and brain ultrasonography was more sensitive than MRI for detecting LSV. However, standard brain ultrasonography has been reported to have the best negative predictive value when done prenatally. 21 Half of the children with symptomatic congenital CMV infections will develop hearing loss 5, 9, 18 ; however, the majority will have a delayed onset or progressive hearing loss. 18 In such cases, anti-CMV medication can be used to prevent progressive hearing impairment. In the present study, the hearing level of one child given an antiviral drug for 1 year rose from 40 dB to 30 dB. Hearing impairment without an identified cause is also suggestive of a CMV infection. Beginning medical treatment early depends on an early diagnosis. Congenital CMV infections and connexin mutations are the two major causes of deafness at birth. 23 Our previous study analyzed patients with nonsyndromic hearing loss in Taiwan, and indicated that mutations of the CX gene family were responsible for w24% of nonsyndromic hearing loss, with the cause of the remaining 76% being unknown. 24 In the current study, we found that three of the 20 newborns with CMV infection had hearing loss. Therefore, we suggest that further studies are necessary to determine whether a CMV infection or other genetic mutations are the major cause of hearing loss.
Ganciclovir therapy for newborns with congenital or perinatal CMV disease, including symptomatic patients with viral sepsis-like syndrome, pneumonitis or severe thrombocytopenia, sight-threatening retinitis, combined with primary immune disorders, and CMV infection has been suggested, 25 as it is believed that patients with symptoms will have better outcomes than those without treatment. However, the side effects of gancylocvir should be considered, which include lethal leucopenia. Newborns with CMVassociated hearing impairment and central nervous system involvement may benefit from long-term antiviral therapy. 25 Ganciclovir therapy of 6 mg/kg per dose administered intravenously every 12 hours for 6 weeks beginning in the neonatal period in symptomatic infants with CMV infection involving the central nervous system has shown apparent protection against hearing loss or progression of the infection and improved head circumference growth and neurodevelopmental milestones for the first 6e12 months of life. 26, 27 Oral ganciclovir is an alternative choice with lesser adverse effects than intravenous administration. For patients without symptoms, no brain involvement or hearing impairment, observation is suggested rather than aggressive treatment which may contribute to unnecessary adverse effects. We had one case with a temporal cyst, thin corpus callosum, white matter change, and hearing impairment who received intravenous and oral ganciclovir treatment for 1 year, and the hearing outcome improved from 40 dB to 30 dB with no obvious adverse effects except for mild intelligence impairment at 4 years of age.
In this study, we found that severe LSV with marked echogenic linear structures contributed to a more positive result, which has not been reported previously. In a study by Makhoul et al 14 on 21 newborns with LSV, only one patient had a congenital CMV infection, which is inconsistent with our study. This difference is probably because the cases of LSV in their study were mild, leading to an underestimated CMV infection rate. The ratio of bilateral LSV in our study was 76%, which is similar to that in other studies. 14, 17 An association of CMV and LSV (10e24% of 34 infants) was reported in study by Wang et al, 17 which is consistent with our study. However, more newborns had severe LSV in our study than in their study. This highlights that the degree of LSV in brain ultrasonography is an important factor associated with CMV infection.
This study has a number of limitations. Firstly, a majority (80%) of the cases were selected from the NICU (level III), and 13% were from the specialty care nursery (level II). The large number of cases from the NICU may have resulted in a larger proportion of cases with CMV infection in our study sample. However, this highlights that newborns in the NICU are at a high risk of CMV infection. In the IUGR group, of the 72 patients without LSV, 33 had CMV detected in urine PCR, possibly because of inconsistent policies of the individual physicians. IUGR is not a specific symptom and normal newborns would have been a better control group. However, investigating normal newborns is difficult which is why we chose those with symptoms of IUGR and without LSV as the control group.
Conclusion
The present study demonstrates that findings of LSV, and particularly severe LSV, in neonatal ultrasonography were correlated with CMV infection. When severe LSV is associated with brain structural anomalies, a congenital CMV infection should be considered. The outcomes of the cases in which CMV infection was associated with other brain structural anomalies were significantly worse than the outcomes in the cases associated with LSV only.
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